Chenomx Inc: Edmonton Software Developer Announces Collaborative Agreement With World's Largest Pharmaceutical R&D Firm.Business Editors EDMONTON, Alberta, Canada--(BUSINESS WIRE)--April 9, 2002 Chenomx Inc., a provider of drug development and clinical diagnostics software, today announced an alliance with Pfizer Global Research and Development (NYSE NYSE See: New York Stock Exchange :PFE 1. (text, editor) PFE - Programmer's File Editor. 2. (language) PFE - Portable Forth Environment. ) to evaluate and enhance Chenomx-developed software. The software, Concurrent Chemical Mixture Analysis (CCMA CCMA Commission for Conciliation, Mediation and Arbitration (South Africa) CCMA Canadian Country Music Association CCMA Customer Contact Management Association CCMA Christian Country Music Association ), was officially unveiled this month. CCMA combines powerful analytical software with nuclear magnetic resonance nuclear magnetic resonance: see magnetic resonance. nuclear magnetic resonance (NMR) Selective absorption of very high-frequency radio waves by certain atomic nuclei subjected to a strong stationary magnetic field. (NMR NMR: see magnetic resonance. ) spectroscopy data to provide one-step analysis of hundreds of compounds in a single sample of urine or blood. Using CCMA to evaluate therapeutics, a drug developer will measure the drug and compounds that could potentially correlate with the body's response to the drug. This metabolic profiling, also known as metabonomics, is a powerful tool used to evaluate the efficacy or toxicity of drug candidates. "Our goal with CCMA is to provide a software solution that automates the previously manual spectral analysis process, to help companies save resources in the drug discovery timeline," said Neil Taylor, president of Chenomx. "By having Pfizer utilize our software, Chenomx can gain insight into the use of the software in order to develop a robust product that meets customer's needs." For more information, or to schedule an interview, contact: Lori Querengesser Business Development Manager, Chenomx Inc. Research Transition Facility 2007, 8308-114th Street Edmonton, Alberta T6G 2E1 Phone: 780.432.0033 Fax: 780.432.3388 lquerengesser@chenomx.com Background Information Chenomx Inc. is a privately held Canadian company that was formed in 2000 to further develop drug discovery software initially conceived by Dr. David Wishart at BioTools Incorporated, an Edmonton-based bioinformatics company. Chenomx, a University of Alberta spin-off company located in Edmonton's Research Transition Facility, has been supported by the Alberta Heritage Foundation for Medical Research (AHFMR AHFMR Alberta Heritage Foundation for Medical Research ) and the Natural Research Council's Industrial Research Assistance Program (IRAP IRAP Industrial Research Assistance Program (National Research Council, Canada) IRAP Imposta Regionale sulle Attività Produttive (Italy) IRAP Interleukin-1 Receptor Antagonist Protein ). More information on Chenomx and its solutions available at www.chenomx.com CCMA is proprietary software developed by Chenomx to offer a cost-effective solution for the often laborious task of NMR spectral interpretation; what once took several hours now takes mere seconds of computing time. The software is provided to the client as stand-alone software, not as a service, thereby allowing customization of the user's databases and in-house control of the results. Chenomx believes this powerful technology will become a mandatory tool for helping speed drugs to market, one of the most important issues facing the pharmaceutical industry today. The development of the Chenomx software has been supported through a strategic research collaboration with Varian, Inc., a world-leader in NMR science and technology. Varian, Inc. (Nasdaq:VARI Va´ri n. 1. (Zool.) The ringtailed lemur (Lemur catta) of Madagascar. Its long tail is annulated with black and white. ) is a major supplier of scientific instruments, vacuum technologies, and specialized contract electronics manufacturing services Electronic manufacturing services (EMS) is term used for companies that design, test, manufacture, distribute and provide return/repair services for electronic component and assemblies for original equipment manufacturers (OEMs). . These activities serve life science, health care, chemical analysis, industrial, and electronics customers worldwide. The company manufactures in 15 locations in North America, Europe and the Pacific Rim, and employs some 4,100 people. Varian, Inc. had fiscal year 2001 sales of $749 million. Additional information is available at www.varianinc.com Pfizer Global Research and Development (NYSE:PFE), the largest pharmaceutical R&D organization in the world, has approximately 12,000 employees worldwide involved in 156 projects in development across 19 therapeutic areas. Pfizer Inc. discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world's best-known consumer products. More information available at: www.pfizer.com Metabolic profiling (also known as metabonomics) enables the complete evaluation of a biological specimen's metabolic status. Previously, examination of a few biomolecules This page aims to list articles on Wikipedia that describe particular biomolecules or types of biomolecules. This list is not necessarily complete or up to date - if you see an article that should be here but isn't (or one that shouldn't be here but is), please update the page or disease markers produced limited information. New generation metabolic profiling methods examine a larger number of metabolites Metabolites Substances produced by metabolism or by a metabolic process. Mentioned in: Interactions or biomarkers simultaneously, producing information that can be more predictive of altered metabolism or disease states. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion